SG10201407013QA - Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases - Google Patents
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseasesInfo
- Publication number
- SG10201407013QA SG10201407013QA SG10201407013QA SG10201407013QA SG10201407013QA SG 10201407013Q A SG10201407013Q A SG 10201407013QA SG 10201407013Q A SG10201407013Q A SG 10201407013QA SG 10201407013Q A SG10201407013Q A SG 10201407013QA SG 10201407013Q A SG10201407013Q A SG 10201407013QA
- Authority
- SG
- Singapore
- Prior art keywords
- pediatric
- treatment
- bile acid
- cholestatic liver
- acid recycling
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
- C07D337/02—Seven-membered rings
- C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161553094P | 2011-10-28 | 2011-10-28 | |
US201261607503P | 2012-03-06 | 2012-03-06 | |
US201261607487P | 2012-03-06 | 2012-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201407013QA true SG10201407013QA (en) | 2014-12-30 |
Family
ID=48168608
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201401849QA SG11201401849QA (en) | 2011-10-28 | 2012-10-26 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
SG10201909122Q SG10201909122QA (en) | 2011-10-28 | 2012-10-26 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
SG10201407013QA SG10201407013QA (en) | 2011-10-28 | 2012-10-26 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201401849QA SG11201401849QA (en) | 2011-10-28 | 2012-10-26 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
SG10201909122Q SG10201909122QA (en) | 2011-10-28 | 2012-10-26 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Country Status (22)
Country | Link |
---|---|
US (9) | US20140243281A1 (pt) |
EP (2) | EP2771003B1 (pt) |
JP (4) | JP6217938B2 (pt) |
KR (2) | KR102051030B1 (pt) |
CN (2) | CN107375932B (pt) |
AU (3) | AU2012328526B2 (pt) |
BR (1) | BR112014010223B8 (pt) |
CA (1) | CA2853285C (pt) |
DK (1) | DK2771003T3 (pt) |
EA (2) | EA030839B1 (pt) |
ES (1) | ES2633766T3 (pt) |
FI (1) | FIC20230019I1 (pt) |
FR (1) | FR23C1022I2 (pt) |
HK (1) | HK1248117A1 (pt) |
IL (2) | IL232150A (pt) |
MX (3) | MX354242B (pt) |
NL (1) | NL301234I2 (pt) |
PL (1) | PL2771003T3 (pt) |
PT (1) | PT2771003T (pt) |
SG (3) | SG11201401849QA (pt) |
WO (1) | WO2013063512A1 (pt) |
ZA (3) | ZA201403368B (pt) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2145327B1 (en) | 2007-04-13 | 2017-08-16 | NIKE Innovate C.V. | Vision cognition and coordination testing |
HUE030062T2 (en) | 2010-11-08 | 2017-04-28 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
US20130108573A1 (en) * | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
CA2907230A1 (en) * | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
MX2016014731A (es) | 2014-05-12 | 2017-05-04 | Conatus Pharmaceuticals Inc | Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa. |
WO2015199147A1 (ja) | 2014-06-25 | 2015-12-30 | 味の素株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
KR101674806B1 (ko) * | 2014-10-20 | 2016-11-10 | 씨제이헬스케어 주식회사 | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 |
CN104324307A (zh) * | 2014-10-24 | 2015-02-04 | 济南高达信息技术有限公司 | 一种治疗脂肪泻的中药口服液制剂及其制备方法 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
LT3300500T (lt) | 2015-05-20 | 2020-05-25 | Amgen Inc. | Apj receptoriaus triazolo agonistai |
KR101632839B1 (ko) | 2015-07-10 | 2016-06-23 | 아주대학교산학협력단 | 레스베라트톨 유도체를 유효성분으로 포함하는 간경화 또는 간섬유화 예방 또는 치료용 약학 조성물 |
US20190022043A1 (en) | 2015-12-31 | 2019-01-24 | Conatus Pharmaceuticals Inc. | Methods of using caspase inhibitors in treatment of liver disease |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
EP3541805B1 (en) | 2016-11-16 | 2020-10-14 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
WO2018093576A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
WO2018097944A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
AU2018223976B2 (en) * | 2017-02-24 | 2023-08-17 | Genfit | Pharmaceutical compositions for combination therapy |
EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
EP3704122B1 (en) | 2017-11-03 | 2021-09-01 | Amgen Inc. | Fused triazole agonists of the apj receptor |
TW201943410A (zh) * | 2018-04-10 | 2019-11-16 | 荷蘭商帝斯曼知識產權資產管理有限公司 | 具有彈性結構之多顆粒固體劑型 |
EP3788037A1 (en) | 2018-05-01 | 2021-03-10 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
BR112020024479A2 (pt) | 2018-06-20 | 2021-03-02 | Albireo Ab | hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica |
US11273123B2 (en) | 2018-07-18 | 2022-03-15 | USpharma Ltd | Chewable pharmaceutical dosage forms |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
AU2020221834A1 (en) * | 2019-02-12 | 2021-09-02 | Mirum Pharmaceuticals, Inc. | Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency |
CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
DK4069360T3 (da) | 2019-12-04 | 2024-02-26 | Albireo Ab | Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer |
EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202134221A (zh) * | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
ES2972045T3 (es) | 2019-12-04 | 2024-06-10 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
CN116157389A (zh) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
EP4243831A1 (en) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
IL308736A (en) * | 2021-05-24 | 2024-01-01 | Astellas Gene Therapies Inc | Compositions and methods for improved treatment of X-linked myotubular myopathy |
TW202333722A (zh) * | 2021-10-26 | 2023-09-01 | 美商米魯姆製藥公司 | 頂端鈉依賴型轉運蛋白抑制劑組合物 |
TW202333723A (zh) * | 2021-10-26 | 2023-09-01 | 美商米魯姆製藥公司 | 頂端鈉依賴型膽酸轉運蛋白抑制劑(asbti)之給藥方法 |
US20230338392A1 (en) | 2022-04-22 | 2023-10-26 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
CN116421590B (zh) * | 2023-06-14 | 2023-08-29 | 深圳市第二人民医院(深圳市转化医学研究院) | 二乙酸氯己定在制备预防或/和治疗肝癌的药物中的用途 |
Family Cites Families (281)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE580490A (fr) | 1958-07-15 | 1960-01-08 | Merck & Co Inc | Compositions et procédés pour abaisser la teneur en cholestérol du sang |
US3383281A (en) | 1961-09-22 | 1968-05-14 | Merck & Co Inc | Method for binding bile acids in vivo |
US3308020A (en) | 1961-09-22 | 1967-03-07 | Merck & Co Inc | Compositions and method for binding bile acids in vivo including hypocholesteremics |
US3287370A (en) | 1965-06-08 | 1966-11-22 | Mcneilab Inc | Tetrahydrobenzothiepins |
US3389144A (en) | 1965-06-08 | 1968-06-18 | Mcneilab Inc | 5-pyridyl-2, 3, 4, 5-tetrahydrobenzothiepin-5-ols |
DE1593760A1 (de) | 1967-02-01 | 1972-06-08 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung neuer Benz-epinderivate |
US3444176A (en) | 1967-04-28 | 1969-05-13 | Mcneilab Inc | Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof |
GB1269551A (en) | 1969-03-27 | 1972-04-06 | Science Union & Cie | New tricyclic derivatives and process for their manufacture |
NL7017227A (pt) | 1969-12-27 | 1971-06-29 | ||
US3694446A (en) | 1970-02-24 | 1972-09-26 | William J Houlihan | 5-(substituted-benzyl)-benzocycloheptenes and-1-benzthiepines |
CH537404A (de) | 1970-09-24 | 1973-05-31 | Sandoz Ag | Verfahren zur Herstellung neuer Thiophenderivate |
CH531000A (de) | 1970-03-11 | 1972-11-30 | Sandoz Ag | Verfahren zur Herstellung neuer Benzocycloheptathiophene |
US3758528A (en) | 1970-03-13 | 1973-09-11 | Science Union & Cie | Tricyclic compounds |
US3821249A (en) | 1970-03-13 | 1974-06-28 | En Nom Collectif Science Union | Dibenzothiazefin derivatives |
GB1348642A (en) | 1970-10-15 | 1974-03-20 | Howard A N | Hypocholesterolaemic compositions |
US3769399A (en) | 1971-03-05 | 1973-10-30 | L Hagerman | Intestinal bile acid binding process and compositions |
GB1428110A (en) | 1972-05-30 | 1976-03-17 | Reckitt & Colmann Prod Ltd | Pharmaceutical antihypertensive and vasodilator compositions |
US3974272A (en) | 1972-09-01 | 1976-08-10 | Merck & Co., Inc. | Palatable cholestyramine coacervate compositions |
CH582699A5 (pt) | 1973-03-26 | 1976-12-15 | Sandoz Ag | |
CH593970A5 (en) | 1973-03-30 | 1977-12-30 | Hoffmann La Roche | 10-(4-Substd. piperazino) dibenzo (b,f) thiepins - CNS depressants without cataleptic side-effects |
US4044010A (en) | 1973-03-30 | 1977-08-23 | Hoffmann-La Roche Inc. | Dibenzo[b,f] thiepins bearing piperazinyl substitution |
US3954764A (en) | 1973-03-30 | 1976-05-04 | Hoffmann-La Roche Inc. | Dibenzo [b,f]thiepins bearing piperazinyl substitution |
US3928383A (en) | 1973-06-08 | 1975-12-23 | Hoffmann La Roche | Propynylamine-substituted dibenzo{8 b,f{9 thiepins and dibenz{8 b,f{9 oxepins |
SE7504508L (sv) | 1974-05-10 | 1975-11-11 | Ciba Geigy Ag | Nya heterocykliska s-imino-s-oxider. |
SE420725B (sv) | 1974-09-26 | 1981-10-26 | Ciba Geigy Ag | Sett att framstella 2,3-dihydro-1-benstiepin-4-karboxylsyraamider |
US4252790A (en) | 1974-10-23 | 1981-02-24 | Interx Research Corporation | Method for treating gastric ulcer-prone patients |
GB1566609A (en) | 1977-03-10 | 1980-05-08 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions containing cholestyramine and alginic acid |
US4251526A (en) | 1977-10-31 | 1981-02-17 | Mccall John M | 2-Benzothiepins and compositions and methods of use therefore |
US4247553A (en) | 1977-10-31 | 1981-01-27 | The Upjohn Company | Methods of treating psychosis |
US4153612A (en) | 1977-10-31 | 1979-05-08 | The Upjohn Company | 2-Benzoxepins |
US4207239A (en) | 1977-10-31 | 1980-06-10 | The Upjohn Company | Benzothiepins |
US4247533A (en) | 1978-05-01 | 1981-01-27 | The Rockefeller University | Hemoglobin A1c radioimmunoassay |
IT1106718B (it) | 1978-12-21 | 1985-11-18 | Alfa Farmaceutici Spa | Composizioni a base di resine anioniche salificate farmacologicamente attive |
US5169857A (en) | 1988-01-20 | 1992-12-08 | Bayer Aktiengesellschaft | 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis |
AU548253B2 (en) | 1981-05-11 | 1985-12-05 | Pierre Fabre S.A. | Benzoxepine derivatives and sulphur and nitrogen analogues thereof |
US4647459A (en) | 1983-07-20 | 1987-03-03 | Warner-Lambert Company | Confectionery compositions containing magnesium trisilicate adsorbates |
US4771072A (en) | 1985-01-10 | 1988-09-13 | Tanabe Seiyaku Co., Ltd. | Alkoxynaphthalene derivatives |
US4747881A (en) | 1985-02-05 | 1988-05-31 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
AU597671B2 (en) | 1986-06-20 | 1990-06-07 | Suntory Limited | 2-Phenylbenzoxepin derivative |
JPS6310746A (ja) | 1986-07-01 | 1988-01-18 | Tanabe Seiyaku Co Ltd | ナフタレン誘導体 |
US4895723A (en) | 1986-09-08 | 1990-01-23 | Amer And Company | Cholestyramine compositions and method for preparation thereof |
US4814354A (en) | 1986-09-26 | 1989-03-21 | Warner-Lambert Company | Lipid regulating agents |
ZA876930B (en) | 1986-10-07 | 1988-05-25 | Hoffmann La Roche | Pharmaceutical compositions |
AU626881B2 (en) | 1988-07-14 | 1992-08-13 | F. Hoffmann-La Roche Ag | Benzofused heterocyclics used as pharmaceuticals |
US5164387A (en) | 1988-07-14 | 1992-11-17 | Hoffmann-Laroche Inc. | Condensed heterocyclic compounds |
US5158943A (en) | 1988-11-21 | 1992-10-27 | Takeda Chemical Industries, Ltd. | Sulfur-containing heterocyclic compounds |
US4874744A (en) | 1989-03-13 | 1989-10-17 | University Of Cincinnati | Method of using melanocyte stimulating hormone as dermatis treatment |
US5275823A (en) | 1989-04-27 | 1994-01-04 | Smith Kline & French Laboratories Ltd. | Pharmaceutical compositions |
DE3930696A1 (de) | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
US4997665A (en) * | 1989-10-05 | 1991-03-05 | Michigan Biotechnology Institute | Dietary fibers and a process for their production |
FR2661676A1 (fr) | 1990-05-02 | 1991-11-08 | Lipha | Derives d'amino benzocycloalcanes, procedes de preparation et medicaments les contenant. |
DK0489423T3 (da) | 1990-12-06 | 1997-04-14 | Hoechst Ag | Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelsen af disse forbindelser som lægemidler |
IT1245890B (it) | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari. |
WO1992018462A1 (en) | 1991-04-12 | 1992-10-29 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
EP0597107B1 (en) | 1991-10-17 | 1996-07-03 | Shionogi & Co., Ltd. | Lignan analog, production thereof, and hypolipidemic drug |
EP0549967B1 (de) | 1991-12-20 | 1996-03-13 | Hoechst Aktiengesellschaft | Polymere und Oligomere von Gallensäurederivaten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
ATE160783T1 (de) | 1992-06-12 | 1997-12-15 | Hoechst Ag | Gallensäurederivate, verfahren zu ihrer herstellung und verwendung dieser verbindungen als arzneimittel |
US5415872A (en) | 1992-06-22 | 1995-05-16 | Digestive Care Inc. | Compositions of gastric acid-resistant microspheres containing salts of bile acids |
FR2698873B1 (fr) | 1992-12-07 | 1995-02-24 | Lipha | Benzocycloheptènes, benzoxépines et benzothiépines activateurs des canaux potassiques, procédé de préparation, composition pharmaceutique les contenant. |
IL108633A (en) | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
US5594001A (en) | 1993-04-08 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders |
JP3411036B2 (ja) | 1993-04-16 | 2003-05-26 | 塩野義製薬株式会社 | リグナン系化合物の製造方法 |
DE4314583A1 (de) | 1993-04-29 | 1994-11-03 | Astra Chem Gmbh | Colestyramin enthaltende Zusammensetzung und Verfahren zu deren Herstellung |
TW289021B (pt) | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
TW289020B (pt) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
EP0624593A3 (de) | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
US5607669A (en) | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
EP0640344B1 (de) * | 1993-08-30 | 1998-10-07 | Medichemie Ag | Ursodeoxycholsäure enthaltendes Arzneimittel in flüssiger Darreichungsform |
US5589358A (en) | 1993-12-29 | 1996-12-31 | Univ Wake Forest | Ileal bile acid transporter compositions and methods |
US5491152A (en) | 1994-03-23 | 1996-02-13 | The Du Pont Merck Pharmaceutical Company | Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis |
TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
KR970005178Y1 (ko) | 1994-07-06 | 1997-05-24 | 김상수 | 개량형 노통연관 보일러 |
ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
WO1996008484A1 (en) | 1994-09-13 | 1996-03-21 | Monsanto Company | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US5994391A (en) | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6268392B1 (en) | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
US6107494A (en) | 1994-09-13 | 2000-08-22 | G.D. Searle And Company | Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US5547975A (en) | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
US6034118A (en) | 1994-11-04 | 2000-03-07 | Gilead Sciences, Inc. | Thiepane compounds |
GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
US6083977A (en) | 1994-12-30 | 2000-07-04 | Ligand Pharmaceuticals Incorporated | Trienoic retinoid compounds and methods |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US5886016A (en) | 1995-09-15 | 1999-03-23 | G.D. Searle & Co. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
WO1997016184A1 (en) | 1995-11-02 | 1997-05-09 | Warner-Lambert Company | Method and pharmaceutical composition for regulating lipid concentration |
AU724620B2 (en) * | 1996-01-16 | 2000-09-28 | Sokol, Ronald J Dr. | Use of antioxidant agents to treat cholestatic liver disease |
GB9601697D0 (en) | 1996-01-27 | 1996-03-27 | Pfizer Ltd | Therapeutic agents |
NZ331813A (en) | 1996-03-11 | 2001-03-30 | G | Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
JP2002508652A (ja) | 1996-08-23 | 2002-03-19 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | 新規なヒト増殖因子 |
JPH1072371A (ja) | 1996-08-28 | 1998-03-17 | Sankyo Co Ltd | 回腸型胆汁酸トランスポーター阻害剤 |
US6251852B1 (en) | 1996-09-18 | 2001-06-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US5908830A (en) | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
GB9704208D0 (en) | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
PL336415A1 (en) | 1997-03-11 | 2000-06-19 | Searle & Co | Combined therapy employing ileic bile acid transport inhibiting benzothiepins as well as a hmg co-enzyme reductase inhibitors |
ES2198613T3 (es) | 1997-03-14 | 2004-02-01 | Aventis Pharma Deutschland Gmbh | 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos. |
DE19845402B4 (de) | 1998-10-02 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
ATE268758T1 (de) | 1997-04-04 | 2004-06-15 | Aventis Pharma Gmbh | Hypolipidämische propanolaminderivate |
IT1292092B1 (it) | 1997-06-05 | 1999-01-25 | Geange Ltd | Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali |
WO1998056757A1 (fr) | 1997-06-11 | 1998-12-17 | Sankyo Company, Limited | Derives de benzylamine |
GB9714274D0 (en) | 1997-07-08 | 1997-09-10 | Zeneca Ltd | Pharmaceutical composition |
US6180660B1 (en) | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
US6066336A (en) | 1997-09-29 | 2000-05-23 | Bristol-Myers Squibb Company | Cholesterol-lowering tablets |
US5900233A (en) | 1997-10-16 | 1999-05-04 | Day; Charles E. | Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome |
US6245797B1 (en) | 1997-10-22 | 2001-06-12 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease |
US6083497A (en) | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
DE19755480A1 (de) | 1997-12-13 | 1999-06-24 | Gruenenthal Gmbh | Substituierte heterocyclische Benzocycloalkene und ihre Verwendung als analgetisch wirksame Substanzen |
HUP0101193A3 (en) | 1997-12-19 | 2001-12-28 | G D Searle & Co Chicago | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides |
GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
CA2319195A1 (en) | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19825804C2 (de) * | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
JP2000026300A (ja) | 1998-07-02 | 2000-01-25 | Pola Chem Ind Inc | 血管内皮細胞保護医薬組成物 |
AU5194999A (en) | 1998-08-07 | 2000-02-28 | Takeda Chemical Industries Ltd. | Benzothiepin derivatives, process for the preparation of the same and uses thereof |
US6096780A (en) | 1998-08-20 | 2000-08-01 | Takeda Chemical Industries, Ltd. | Quaternary ammonium salts and their use |
DE19845406C2 (de) | 1998-10-02 | 2001-10-18 | Aventis Pharma Gmbh | Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE19845403B4 (de) | 1998-10-02 | 2005-02-10 | Aventis Pharma Deutschland Gmbh | Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE19845405C2 (de) | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
AU1684400A (en) | 1998-12-11 | 2000-07-03 | Sankyo Company Limited | Substituted benzylamines |
CA2353635A1 (en) | 1998-12-21 | 2000-06-29 | Takeda Chemical Industries, Ltd. | Anilide derivative, production and use thereof |
AU776953B2 (en) | 1998-12-23 | 2004-09-30 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications |
CA2356422C (en) | 1998-12-23 | 2008-09-16 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
CA2356607A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
EP1354604A1 (en) | 1998-12-23 | 2003-10-22 | G.D. Searle LLC. | Combinations for cardiovascular indications |
HUP0105409A3 (en) | 1999-02-12 | 2004-11-29 | G D Searle Llc Chicago | 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake, use thereof and pharmaceutical compositions containing them |
CN1095238C (zh) | 1999-02-23 | 2002-11-27 | 东京零件工业株式会社 | 适应回流锡焊的小型电动机 |
DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
TR200002099A3 (tr) | 1999-07-22 | 2001-06-21 | Sankyo Company Limited | Siklobüten türevleri, bunlarin hazirlanmasi ve terapötik kullanimlari |
DE60034954D1 (de) | 1999-09-14 | 2007-07-05 | Xenoport Inc | Substrate und screeningverfahren für transportproteine |
WO2001034570A1 (fr) | 1999-11-08 | 2001-05-17 | Sankyo Company, Limited | Derives heterocycliques azotes |
US20020004065A1 (en) * | 2000-01-20 | 2002-01-10 | David Kanios | Compositions and methods to effect the release profile in the transdermal administration of active agents |
DE122008000018I1 (de) | 2000-01-21 | 2008-08-14 | Novartis Pharma Ag | Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica |
WO2001066096A2 (en) | 2000-03-06 | 2001-09-13 | Immune Network Ltd. | Compositions for prevention and treatment of dementia |
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
AU2001247331A1 (en) | 2000-03-10 | 2001-09-24 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
JP2003528830A (ja) | 2000-03-10 | 2003-09-30 | ファルマシア・コーポレーション | テトラヒドロベンゾチエピン類の製造方法 |
EP1273659A4 (en) | 2000-04-12 | 2004-04-21 | Takeda Chemical Industries Ltd | NOVEL G PROTEIN-COUPLED RECEPTOR PROTEIN AND DNA THEREOF |
IT1316130B1 (it) | 2000-05-18 | 2003-03-28 | High Technology Investiments B | Impianto motore con apparecchiatura per il comando di disinserimento efermata regolato e/o modulato di una funivia. |
BR0112530B1 (pt) | 2000-07-17 | 2012-05-02 | processo para preparar derivados de 4-tioalquilbromobenzeno. | |
US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
PT1307264E (pt) | 2000-07-28 | 2005-02-28 | Hoffmann La Roche | Nova composicao farmaceutica |
SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
JP4003069B2 (ja) | 2000-11-17 | 2007-11-07 | 萬有製薬株式会社 | 新規なグアノシン三リン酸(gtp)結合タンパク質共役型のレセプタータンパク質、bg37 |
BR0116325A (pt) | 2000-12-21 | 2003-10-14 | Aventis Pharma Gmbh | 1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
DK1353694T3 (da) | 2001-01-26 | 2008-03-25 | Schering Corp | Kombinationer af ezetimibe med aspirin til behandling af vaskulære tilstande |
WO2002078625A2 (en) | 2001-03-28 | 2002-10-10 | Pharmacia Corporation | Therapeutic combinations for cardiovascular and inflammatory indications |
BR0211274A (pt) | 2001-07-19 | 2004-08-03 | Pharmacia Corp | Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase |
JP2005501861A (ja) | 2001-08-22 | 2005-01-20 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 1,4−ベンゾチエピン1,1−ジオキシド誘導体と他の活性物質との組合わせ剤及びそれらの使用 |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
NZ531796A (en) | 2001-09-08 | 2005-10-28 | Astrazeneca Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia |
US7227019B2 (en) | 2001-09-13 | 2007-06-05 | Bristol-Myers Squibb Company | Process for the preparation of rebeccamycin and analogs thereof |
WO2003026643A2 (en) | 2001-09-21 | 2003-04-03 | Schering Corporation | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
CA2776522C (en) | 2001-10-01 | 2015-02-17 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
WO2003040127A1 (en) | 2001-11-02 | 2003-05-15 | G.D. Searle Llc | Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake |
JP2005521653A (ja) | 2002-01-17 | 2005-07-21 | ファルマシア コーポレイション | 先端ナトリウム同時依存性胆汁酸輸送(asbt)およびタウロコール酸塩取込みの阻害剤としての新規アルキル/アリールヒドロキシまたはケトチエピン化合物 |
GB0201850D0 (en) | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
US20040014806A1 (en) | 2002-03-08 | 2004-01-22 | Pharmacia Corporation | Methods and compositions for lowering levels of blood lipids |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
US6987121B2 (en) | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
BR0311530A (pt) | 2002-05-23 | 2005-05-10 | Umd Inc | Compostos e método de liberação para droga transmucosal e para crio-proteção |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
US6861464B2 (en) | 2002-07-19 | 2005-03-01 | Diversified Chemical Technologies, Inc. | Two component, curable, hot melt adhesive |
ATE531701T1 (de) * | 2002-08-28 | 2011-11-15 | Asahi Kasei Pharma Corp | Neue quaternüre ammoniumverbindungen |
US7312208B2 (en) | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
MXPA05004810A (es) | 2002-11-06 | 2005-07-22 | Schering Corp | Inhibidores de la absorcion del colesterol para el tratamiento de la desmielinizacion. |
US20040122033A1 (en) | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
US20040138145A1 (en) | 2002-12-12 | 2004-07-15 | Aventis Pharma S.A. | Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease |
FR2848452B1 (fr) | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
US20040147774A1 (en) | 2002-12-20 | 2004-07-29 | Aventis Pharma S.A. | Novel chiral compounds derived from hexanoic acid esters, preparation process and intermediates, use in the synthesis of chiral 2-(bromomethyl)-2-ethylhexanoic acid |
US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
EP1601669B1 (en) | 2003-03-07 | 2008-12-24 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
US7192944B2 (en) | 2003-03-07 | 2007-03-20 | Schering Corp. | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
JP4509100B2 (ja) | 2003-05-08 | 2010-07-21 | ノボ・ノルデイスク・エー/エス | 取り外し可能な針挿入作動部を有する皮膚に取り付け可能な注入装置 |
JP2005044778A (ja) | 2003-07-19 | 2005-02-17 | Samsung Sdi Co Ltd | 電界発光素子 |
JP2005097216A (ja) | 2003-09-26 | 2005-04-14 | Kaneka Corp | PPARγリガンド剤 |
WO2005046797A2 (en) | 2003-11-05 | 2005-05-26 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
EP1564554A1 (en) | 2004-02-12 | 2005-08-17 | Pepscan Systems B.V. | Method for the detection of early B cell populations in vaccine development |
CA2557576C (en) * | 2004-02-27 | 2010-02-09 | Asahi Kasei Pharma Corporation | Novel benzothiazepine and benzothiepine compounds |
DE102004016845A1 (de) | 2004-04-07 | 2005-10-27 | Bayer Healthcare Ag | Phenylthioessigsäure-Derivate und ihre Verwendung |
WO2006017257A2 (en) | 2004-07-12 | 2006-02-16 | Phenomix Corporation | Azetidinone derivatives |
JP2008513465A (ja) | 2004-09-15 | 2008-05-01 | ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ | 肥満及び糖尿病の治療におけるerストレス低減 |
DE102004046623A1 (de) | 2004-09-25 | 2006-03-30 | Bayer Healthcare Ag | Neue Pyrimidin-Derivate und ihre Verwendung |
CA2581596A1 (en) | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
JPWO2006041150A1 (ja) | 2004-10-15 | 2008-05-22 | 田辺三菱製薬株式会社 | 糖尿病の予防および/または治療薬 |
CA2581298A1 (en) | 2004-10-25 | 2006-05-04 | Novartis Ag | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
AU2004325203A1 (en) | 2004-11-24 | 2006-06-01 | Seo Hong Yoo | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
DE102004058062A1 (de) | 2004-12-02 | 2006-06-08 | Bayer Healthcare Ag | Cyclische Iminocarbamate und ihre Verwendung |
ES2435790T3 (es) | 2004-12-03 | 2013-12-23 | Intervet International B.V. | Piperazinas sustituidas como antagonistas de CB1 |
US20070032420A1 (en) | 2005-02-09 | 2007-02-08 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
US7441178B2 (en) | 2005-02-24 | 2008-10-21 | Keyeye Communications | Low complexity decoding of low density parity check codes |
US20060193895A1 (en) | 2005-02-25 | 2006-08-31 | Use-Techno Corporation | Additive for food and beverage, pharmaceutical composition, GLUT4 translocator, and method for translocating GLUT4 |
DE102005027150A1 (de) | 2005-03-12 | 2006-09-28 | Bayer Healthcare Ag | Pyrimidincarbonsäure-Derivate und ihre Verwendung |
FR2883284A1 (fr) | 2005-03-15 | 2006-09-22 | Commissariat Energie Atomique | Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux |
PE20061245A1 (es) | 2005-03-30 | 2007-01-06 | Generex Pharm Inc | Composiciones para la transmision transmucosa oral de la metformina |
US20080031968A1 (en) | 2005-04-01 | 2008-02-07 | The Brigham And Women's Hospital, Inc. | Methods for increasing cellular energy expenditure |
CA2603452A1 (en) | 2005-04-04 | 2006-10-12 | Julius-Maximillians-Universitat Wurzburg | Tripeptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1 |
US8207133B1 (en) | 2005-04-04 | 2012-06-26 | Julius-Maximilians-Universitat Wurzburg | Peptides that down regulate the activity of plasma membrane transporters including sodium-D-glucose cotransporter SGLT1 |
JP2008539255A (ja) | 2005-04-26 | 2008-11-13 | マイクロビア インコーポレーテッド | 高コレステロール血症のための4−ビアリーリル−1−フェニルアゼチジン−2−オングルクロニド誘導体 |
DE102005020229A1 (de) | 2005-04-30 | 2006-11-09 | Bayer Healthcare Ag | Verwendung von Indolin-Phenylsulfonamid-Derivaten |
US20090074895A1 (en) | 2005-05-02 | 2009-03-19 | Vanadis Bioscience Ltd | Composition and uses thereof |
WO2006121861A2 (en) | 2005-05-05 | 2006-11-16 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
WO2006122186A2 (en) | 2005-05-10 | 2006-11-16 | Microbia, Inc. | 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia |
WO2006124713A2 (en) | 2005-05-13 | 2006-11-23 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-ones |
DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
US20070025953A1 (en) | 2005-07-27 | 2007-02-01 | Jones Michael R | Co-therapy for diabetic conditions |
US7332604B2 (en) | 2005-09-20 | 2008-02-19 | Schering Corporation | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine |
AU2006297130B2 (en) | 2005-09-30 | 2009-12-24 | Novartis Ag | DPP IV inhibitor for use in the treatment of autoimmune diseases and graft rejection |
US8366650B2 (en) | 2005-10-24 | 2013-02-05 | Satiogen Pharmaceuticals, Inc. | Biliary/pancreatic shunt device and method for treatment of metabolic and other diseases |
JP5081161B2 (ja) | 2005-12-19 | 2012-11-21 | スミスクライン ビーチャム コーポレーション | ファルネソイドx受容体アゴニスト |
BRPI0620255A2 (pt) | 2005-12-21 | 2011-11-08 | Schering Corp | uso de agentes redutores de colesterol e/ou antagonista/agonista inverso do receptor de h3 |
US20070203183A1 (en) | 2006-01-13 | 2007-08-30 | Schering Corporation | Diaryl piperidines as CB1 modulators |
CA2637565A1 (en) | 2006-01-18 | 2007-07-26 | Schering Corporation | Cannibinoid receptor modulators |
EA200801551A1 (ru) | 2006-01-20 | 2009-02-27 | Смитклайн Бичем Корпорейшн | Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы |
AU2007215207A1 (en) | 2006-02-14 | 2007-08-23 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions |
DE102006009813A1 (de) | 2006-03-01 | 2007-09-06 | Bayer Healthcare Ag | Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel |
WO2007123949A2 (en) | 2006-04-21 | 2007-11-01 | Schering Corporation | Cannabinoid receptor modulators |
DE102006024024A1 (de) | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
DE102006026585A1 (de) | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Substituierte 4-Aryl-1,4-dihydro-1,6-naphthyridine und ihre Verwendung |
DE102006026583A1 (de) | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung |
WO2008002573A2 (en) | 2006-06-27 | 2008-01-03 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions |
US20080065136A1 (en) | 2006-08-30 | 2008-03-13 | Andrew Young | Distender device and method for treatment of obesity and metabolic and other diseases |
DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
DE102006043520A1 (de) | 2006-09-12 | 2008-03-27 | Bayer Healthcare Ag | 2-Phenoxynikotinsäure-Derivate und ihre Verwendung |
DE102006043519A1 (de) | 2006-09-12 | 2008-03-27 | Bayer Healthcare Ag | 4-Phenoxynikotinsäure-Derivate und ihre Verwendung |
US20080070890A1 (en) | 2006-09-15 | 2008-03-20 | Burnett Duane A | Spirocyclic Azetidinone Compounds and Methods of Use Thereof |
CA2663947A1 (en) | 2006-09-15 | 2008-03-20 | Schering Corporation | Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism |
CN101528227A (zh) | 2006-09-15 | 2009-09-09 | 先灵公司 | 氮杂环丁酮衍生物及其使用方法 |
JP2010503679A (ja) | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | 疼痛および脂質代謝障害を処置する際に有用なアゼチジン誘導体およびアゼチドン誘導体 |
CA2663500A1 (en) | 2006-09-15 | 2008-03-20 | Schering Corporation | Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism |
CN101534822A (zh) | 2006-09-15 | 2009-09-16 | 先灵公司 | 治疗疼痛、糖尿病和脂质代谢紊乱 |
CN101583612A (zh) | 2006-09-15 | 2009-11-18 | 先灵公司 | 治疗脂质代谢障碍的氮杂环丁酮衍生物 |
US20080070984A1 (en) | 2006-09-15 | 2008-03-20 | Tran Pierre V | Compositions and Methods of Treating Schizophrenia |
DE102006044696A1 (de) | 2006-09-22 | 2008-03-27 | Bayer Healthcare Ag | 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung |
WO2008039829A2 (en) | 2006-09-26 | 2008-04-03 | Ironwood Pharmaceuticals, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
CL2007003035A1 (es) | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
WO2008052044A2 (en) | 2006-10-26 | 2008-05-02 | Xenoport, Inc. | Use of derivatives of propofol for treating diseases associated with oxidative stress |
DE102006053635B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
WO2008058631A1 (de) | 2006-11-14 | 2008-05-22 | Sanofi-Aventis Deutschland Gmbh | Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
DE102006053637B4 (de) * | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
US20090035306A1 (en) | 2006-11-29 | 2009-02-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
DE102006056740A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
DE102006056739A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
US20090074785A1 (en) | 2007-01-16 | 2009-03-19 | Smith Jeffrey W | Compositions and methods for treatment of colorectal cancer |
CN101679476B (zh) | 2007-01-19 | 2014-05-07 | 英特塞普特医药品公司 | 23取代的胆汁酸作为tgr5调节剂及其使用方法 |
US20080221161A1 (en) | 2007-02-09 | 2008-09-11 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
US20100144864A1 (en) | 2007-04-05 | 2010-06-10 | Ironwood Pharmaceuticals, Inc. | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders |
WO2008130616A2 (en) | 2007-04-19 | 2008-10-30 | Schering Corporation | Diaryl morpholines as cb1 modulators |
AU2008288770B2 (en) | 2007-08-23 | 2014-06-12 | Theracosbio, Llc | Benzylbenzene derivatives and methods of use |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
EA020310B1 (ru) | 2008-07-30 | 2014-10-30 | Интерсепт Фармасьютикалз, Инк. | Модуляторы рецептора tgr5 и их применение |
PL2376519T3 (pl) | 2008-11-19 | 2014-04-30 | Intercept Pharmaceuticals Inc | Modulatory TGR5 i sposoby ich zastosowania |
CA2744697C (en) | 2008-11-26 | 2016-06-21 | Satiogen Pharmaceuticals, Inc. | Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes |
JP2012509891A (ja) | 2008-11-26 | 2012-04-26 | サティオゲン ファーマシューティカルズ,インク. | 肥満症及び糖尿病を治療するための胆汁酸再循環阻害剤 |
US20110065676A1 (en) | 2009-06-24 | 2011-03-17 | Schering Corporation | Combination therapies comprising par1 antagonists with nar agonists |
AU2010286253A1 (en) * | 2009-08-25 | 2012-04-19 | Victor Ling | Polyhydroxylated bile acids for treatment of biliary disorders |
WO2011075539A2 (en) | 2009-12-18 | 2011-06-23 | Satiogen Pharmaceuticals, Inc. | Treatment of obesity or diabetes with bile acid sequestrants |
WO2011150286A2 (en) | 2010-05-26 | 2011-12-01 | Satiogen Pharmaceuticals,Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
US20120114588A1 (en) | 2010-11-08 | 2012-05-10 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
EP2637667A4 (en) | 2010-11-08 | 2014-06-25 | Albireo Ab | IBAT HEMMER FOR THE TREATMENT OF METABOLISM DISEASES AND RELATED ACCIDENTS |
HUE030062T2 (en) * | 2010-11-08 | 2017-04-28 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
PT2637646T (pt) | 2010-11-08 | 2016-08-17 | Albireo Ab | Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar |
US20130022551A1 (en) * | 2011-07-22 | 2013-01-24 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
US20130108573A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
CA2907230A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
EP4233910A3 (en) | 2016-03-31 | 2024-01-17 | Genfit | Methods of treatment of cholestatic diseases |
US11478440B2 (en) | 2017-04-18 | 2022-10-25 | Genfit | Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent |
-
2012
- 2012-10-26 JP JP2014539087A patent/JP6217938B2/ja active Active
- 2012-10-26 EP EP12801442.0A patent/EP2771003B1/en active Active
- 2012-10-26 MX MX2014005121A patent/MX354242B/es active IP Right Grant
- 2012-10-26 BR BR112014010223A patent/BR112014010223B8/pt active IP Right Grant
- 2012-10-26 DK DK12801442.0T patent/DK2771003T3/en active
- 2012-10-26 EP EP17166814.8A patent/EP3266457A1/en active Pending
- 2012-10-26 PT PT128014420T patent/PT2771003T/pt unknown
- 2012-10-26 SG SG11201401849QA patent/SG11201401849QA/en unknown
- 2012-10-26 MX MX2018002094A patent/MX369466B/es unknown
- 2012-10-26 KR KR1020147014266A patent/KR102051030B1/ko active IP Right Grant
- 2012-10-26 WO PCT/US2012/062284 patent/WO2013063512A1/en active Application Filing
- 2012-10-26 SG SG10201909122Q patent/SG10201909122QA/en unknown
- 2012-10-26 EA EA201490876A patent/EA030839B1/ru not_active IP Right Cessation
- 2012-10-26 KR KR1020197034944A patent/KR20190134828A/ko not_active Application Discontinuation
- 2012-10-26 SG SG10201407013QA patent/SG10201407013QA/en unknown
- 2012-10-26 ES ES12801442.0T patent/ES2633766T3/es active Active
- 2012-10-26 US US14/354,548 patent/US20140243281A1/en not_active Abandoned
- 2012-10-26 CA CA2853285A patent/CA2853285C/en active Active
- 2012-10-26 PL PL12801442T patent/PL2771003T3/pl unknown
- 2012-10-26 CN CN201710187916.6A patent/CN107375932B/zh active Active
- 2012-10-26 EA EA201891154A patent/EA201891154A1/ru unknown
- 2012-10-26 CN CN201280065637.8A patent/CN104023727B/zh active Active
- 2012-10-26 US US13/662,387 patent/US20130109671A1/en not_active Abandoned
- 2012-10-26 AU AU2012328526A patent/AU2012328526B2/en active Active
-
2013
- 2013-04-19 US US13/866,906 patent/US20130338093A1/en not_active Abandoned
-
2014
- 2014-04-22 IL IL232150A patent/IL232150A/en active IP Right Grant
- 2014-04-28 MX MX2019013263A patent/MX2019013263A/es unknown
- 2014-05-12 ZA ZA2014/03368A patent/ZA201403368B/en unknown
-
2016
- 2016-04-25 US US15/137,323 patent/US10512657B2/en active Active
-
2017
- 2017-08-09 AU AU2017213485A patent/AU2017213485B2/en active Active
- 2017-08-15 ZA ZA2017/05523A patent/ZA201705523B/en unknown
- 2017-09-08 US US15/699,478 patent/US20170368085A1/en not_active Abandoned
- 2017-09-11 JP JP2017174408A patent/JP6443950B2/ja active Active
- 2017-10-17 IL IL255090A patent/IL255090B2/en unknown
-
2018
- 2018-06-13 HK HK18107669.5A patent/HK1248117A1/zh unknown
- 2018-11-21 JP JP2018218627A patent/JP7237544B2/ja active Active
-
2019
- 2019-02-04 ZA ZA2019/00729A patent/ZA201900729B/en unknown
- 2019-04-24 AU AU2019202884A patent/AU2019202884C1/en active Active
- 2019-11-11 US US16/679,864 patent/US11229661B2/en active Active
- 2019-11-11 US US16/679,894 patent/US20200069715A1/en not_active Abandoned
-
2021
- 2021-10-11 US US17/498,586 patent/US11376251B2/en active Active
-
2022
- 2022-04-27 US US17/730,737 patent/US20220265649A1/en active Pending
- 2022-11-11 JP JP2022181456A patent/JP2023022082A/ja active Pending
-
2023
- 2023-05-24 FI FIC20230019C patent/FIC20230019I1/fi unknown
- 2023-05-25 FR FR23C1022C patent/FR23C1022I2/fr active Active
- 2023-06-08 NL NL301234C patent/NL301234I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201407013QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
SG10201903512SA (en) | Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases | |
WO2014144650A3 (en) | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease | |
WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
BR112014003225A2 (pt) | profármacos de treprostinil ligados a veículo | |
EA201300121A1 (ru) | Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения | |
MX2011008448A (es) | Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia. | |
WO2013052699A3 (en) | Novel quinoxaline inhibitors of pi3k | |
NZ618734A (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
IL221764A (en) | Use of bile acid sulfate to make pharmaceutical preparations for the treatment of fxr-related diseases | |
EA201490653A1 (ru) | Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств | |
WO2011109262A3 (en) | Cancer diagnosis and imaging | |
BR112012017691A2 (pt) | nova composição | |
BR112014011336A2 (pt) | composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele | |
FR2978046B1 (fr) | Formes posologiques pharmaceutiques de baclofene intrathecal et systeme d'administration associe | |
PH12015502560B1 (en) | Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease | |
EA201592261A1 (ru) | Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой | |
EA201591218A1 (ru) | Способы и композиции для введения оксибутинина | |
MX2015013196A (es) | Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett. | |
WO2011026193A8 (en) | Cytotoxic compounds | |
CU20110050A7 (es) | Método de administración de una composición farmacéutica a un paciente que lo necesita |